These observations suggest that targeting MT1B—and potentially other MTs isoforms—could offer a novel strategy to counteract lipid dysregulation, inflammation, and fibrotic progression in metabolic dysfunction–associated liver diseases. The gene discussed is MT1B; the disease is liver disorder.